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Abstract
Background
The use of circulating tumor cells (CTCs) as an early diagnostic biomarker and prognostic
indicator after surgery or chemotherapy has been suggested for various cancers. This study
aimed to evaluate CTCs in patients who underwent gastrectomy for gastric cancer and to
explore their clinical usefulness in the early diagnosis of gastric cancer.
Methods
A total of 116 patients with gastric cancer who underwent gastrectomy and 31 healthy volun-
teers were prospectively included between 2014 and 2015. Peripheral blood samples were
collected before gastrectomy, and CTCs were examined using a centrifugal microfluidic sys-
tem with a new fluid-assisted separation technique.
Results
After creating a receiver operating characteristic curve to identify the discriminative CTC
value needed differentiate patients with gastric cancer from healthy volunteers, sensitivity
and specificity were nearly optimized at a CTC threshold of 2 per 7.5 mL of blood. Of the 102
persons with a CTC level2 per 7.5 mL of blood, 99 (97.1%) had gastric cancer, and of
the 45 persons with a CTC level <2 per 7.5 mL of blood, 28 (62.2%) were healthy controls.
Accordingly, the sensitivity and specificity for the differentiation of patients with gastric can-
cer from healthy controls were 85.3% and 90.3%, respectively. However, the presence of
CTCs was not associated with any clinicopathologic features such as staging, histologic
type, or mucin phenotype.
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Conclusion
Although we could not prove the clinical feasibility of CTCs for gastric cancer staging, our
results suggest a potential role of CTCs as an early diagnostic biomarker of gastric cancer.
Introduction
Gastric cancer is the fifth-most common malignancy and second-leading cause of cancer-
related death worldwide [1]. Although advances in surgery and adjuvant chemotherapy have
improved the clinical prognoses of patients with gastric cancer [2], the 5-year survival rate
remains<30%, and affected patients are hindered by recurrence and distant metastasis [3].
Circulating tumor cells (CTCs) have been detected in blood from patients with gastric can-
cer [4–6]. These cells may provide useful prognostic information after surgery or chemother-
apy, and may serve as an early cancer diagnostic marker. Previous reports have described
various CTC detection methods based on molecular approaches, such as reverse transcriptase-
polymerase chain reaction (RT-PCR) analysis, in patients with gastric cancer [7]. However, the
ideal CTC detection method should focus directly on tumor cells rather than indirectly linked
surrogate markers via a molecular approach [8, 9].
To identify CTCs directly in blood, we recently developed a centrifugal microfluidic system
based on a new fluid-assisted separation technique (FAST), in which size-based separation
occurs within a centrifugal microfluidic device at a liquid-liquid interface, instead of the con-
ventional liquid-gas interface [10, 11]. In a previous study, we showed that FAST enabled the
highly sensitive, selective, rapid, and label-free isolation of CTCs from whole blood without
prior sample treatment [10].
Although several studies have shown that CTCs can facilitate gastric cancer diagnosis, prog-
nostic evaluation, and anti-cancer therapy response monitoring [5, 6, 12, 13], the clinicopatho-
logic significance of CTCs remains unclear. Therefore, the present study aimed to evaluate
CTCs in patients who underwent gastrectomy for gastric cancer using FAST and to explore
the clinical usefulness of these cells in early gastric cancer diagnosis. Furthermore, we evalu-
ated differences in clinicopathologic features according to the level of CTCs.
Methods
Clinical study design
Patients with gastric cancer who underwent gastrectomy with lymph node dissection at Pusan
National University Hospital (Busan, Korea) were prospectively included. We evaluated the
usefulness of CTCs regarding clinicopathologic findings in patients with gastric cancer. A total
of 131 consecutive patients with gastric cancer were enrolled at our hospital between August
2014 and December 2015. Fifteen patients were excluded from the analysis, including 12
patients who underwent gastrectomy due to non-curative resection of early gastric cancer by
endoscopic submucosal dissection, 2 patients who underwent total gastrectomy for recurrence
of gastric cancer after previous subtotal gastrectomy, and 1 patient who had a simultaneous
colon cancer. Finally, 116 patients were included in the analysis. Peripheral blood samples
were collected before gastrectomy. Written informed consent was obtained from all patients
before they underwent blood sampling, and the study protocol was reviewed and approved by
the Institutional Review Board of Pusan National University Hospital (H-1412-011-024).
Circulating tumor cells in patients with gastric cancer
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Surgical procedures
Laparoscopy-assisted or open gastrectomy was performed with lymphadenectomy, resection,
and reconstruction [14]. In laparoscopy-assisted gastrectomy, a laparoscope and trocars were
inserted through small incisions in the abdominal wall under general anesthesia. Decisions
regarding the appropriate range for surgical operation were based on the degree of cancer pro-
gression, histopathological diagnosis of the biopsy specimen, tumor location, and risks of
lymph node metastasis, morbidity, and mortality. In cases with proximally located tumors,
near-total or total gastrectomies were performed using Billroth-I or Billroth-II and Roux-en-Y
reconstruction methods. Subtotal gastrectomies were performed for tumors located in the
middle third or lower third of the stomach. D1 or D2 lymphadenectomies were performed on
a case-by-case basis.
Histological assessment
The resected specimens were fixed in 10% buffered formalin. Carcinomas and adjacent non-
neoplastic mucosal tissues were serially cut into parallel 5-mm sections, embedded in paraffin,
sectioned, and stained with hematoxylin and eosin for histological examination. Tumor size,
invasion depth, ulceration, degree of differentiation, and lymphovascular invasion were evalu-
ated microscopically according to the Japanese Classification of Gastric Carcinomas [15]. The
seventh edition of the American Joint Committee on Cancer classification system was used for
tumor-node-metastasis staging [16].
Immunohistochemical expression levels of MUC2 (Ccp58, 1:500; Novocastra Laboratories,
Newcastle, UK), MUC5AC (CLH2, 1:500; Novocastra Laboratories), MUC6 (CLH5, 1:500;
Novocastra Laboratories), and CD10 (56C6, 1:100; Novocastra Laboratories) in cancer cells
were evaluated [17]. Briefly, 5-μm-thick consecutive tumor sections were deparaffinized and
hydrated through a graded series of alcohol concentrations. Antigen retrieval was performed
in 10 mmol/L citrate buffer (pH 6.0) in a microwave oven for 10 min, after which endogenous
peroxidase activity was inhibited by immersing the sections in a 3% H2O2/methanol solution.
The sections were incubated with primary antibodies and thoroughly washed in phosphate-
buffered saline (PBS). Next, sections were incubated successively with biotinylated secondary
antibody and avidin-biotinylated horseradish peroxidase complex (Vectastain Elite ABC kit;
Vector Laboratories30, Burlingame, CA, USA). Antibody binding was visualized using 3,3’-
diaminobenzidine tetrachloride as the chromogen, and nuclei were counterstained with
Mayer’s hematoxylin. Immunostaining was considered positive if10% of the cancer cells
were immunoreactive [17, 18]. Mucin phenotypes were classified into 4 types, gastric, intesti-
nal, gastrointestinal, and null, depending on the expression of gastric mucins (MUC5AC and
MUC6) and intestinal mucins (MUC2 and CD10). MUC5AC, MUC6, MUC2, and CD10 are
specifically expressed in the gastric foveolar epithelium, pyloric gland cells, goblet cells, and
brush border, respectively [19].
Isolation and enumeration of circulating tumor cells
Three to five-milliliter blood samples were collected in K2-EDTA tubes after discarding the
first 2 mL of blood to avoid contamination with skin epithelial cells; each sample was inverted
10 times immediately after collection. To prevent cell damage, blood samples were used within
8 hr. All evaluations were performed by technical assistants without knowledge of the patients’
clinical statuses.
The “FAST disc” centrifugal microfluidic system, which conducts size-selective CTC isola-
tion through membrane pores filled with a stably held liquid throughout the filtration process,
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was used to detect CTCs [10, 11]. FAST disc isolation of CTCs allows the use of whole blood
without any sample treatment steps (e.g., dilution and red blood cell lysis).
Before CTC isolation, the disk surface was passivated with bovine serum albumin; a 1%
bovine serum albumin solution was injected into the disc and removed to the waste chamber
after 30-min incubation. Next, the disc surface was washed with 1 mL of PBS. After surface pas-
sivation, 3 mL of unprepared whole blood was introduced to the disc to isolate CTCs. CTCs were
isolated on the membrane by rotating the disc using a programmed spin program. The total pro-
cess time, including whole blood filtration and filter washing with PBS, was less than 1.0 min.
To identify the number of isolated CTCs from sample blood, the disc was immunostained.
First, captured cells were fixed with 4% formaldehyde for 15 min at room temperature. Fixed
cells were permeabilized with 0.1% Triton X-100 in PBS for 5 min and subsequently washed
with PBS. Next, samples were blocked with 20 μg/mL IgG, followed by staining with several
antibodies. An anti-CD45 solution (H130; Life Technologies, Carlsbad, CA, USA) was applied
for 20 min to stain white blood cells, and samples were then washed with 0.01% Tween 20 in
PBS. To stain CTCs, a mixture of FITC-conjugated anti-cytokeratin (CK) (CAM5.2; BD,
Franklin Lakes, NJ, USA), Alexa 488-conjugated anti-pan-CK (AE1/AE3; eBioscience, San
Diego, CA, USA), and FITC-conjugated anti-epithelial cell adhesion molecule (EpCAM) (9C4;
BioLegend, San Diego, CA, USA) was used. This mixture was added to the filter, incubated for
20 min, and followed by washing with 0.01% Tween 20 in PBS. Finally, cell nuclei were stained
with 4,6-diamidino-2-phenylindole (DAPI). To visualize CTCs on the filter, fluorescent
images were taken using an Eclipse Ti-E fluorescence microscope (Nikon, Tokyo, Japan) at
40× magnification. Captured cells were identified as CTCs if they were CK+ or EpCAM+,
CD45-, and DAPI+, and their diameter was> 8 μm (Fig 1). Results are expressed as the num-
ber of CTCs per 7.5 mL of whole blood.
For the control group, peripheral blood samples were obtained from 31 healthy volunteers
who consented to participate. These volunteers had no current illnesses or previous or family
histories of cancer.
Statistical analysis
A receiver operating characteristic (ROC) curve was created to determine the optimal threshold
values for sensitivity and specificity that would best differentiate patients with gastric cancer
from healthy controls. The sensitivity, specificity, and positive and negative predictive values for
the CTC level that would differentiate patients with gastric cancer from healthy controls were
expressed with 95% confidence intervals. Differences in clinicopathologic features and mucin
expression were evaluated according to CTC level using the chi-square test or Fisher’s exact test.
Statistical calculations were performed using IBM SPSS version 21.0 for Windows (IBM Co.,
Armonk, NY). Results were considered statistically significant when the P value was<0.05.
Results
Baseline clinicopathologic characteristics of patients with gastric cancer
The clinicopathologic characteristics of the 116 patients who underwent gastrectomy for gastric
cancer are summarized in Table 1. The patients included 74 male and 42 female patients, with a
median age of 60 years (range, 33–89 years). Twenty-one tumors were located in the upper
third, 43 in the middle third, and 52 in the lower third of the stomach. Ninety-seven patients
underwent subtotal gastrectomy (laparoscopic in 50 patients, open in 47 patients), and 19
patients underwent total gastrectomy (laparoscopic in 2 patients, open in 17 patients). The
median tumor size was 4 cm (range, 2–13 cm). For pathologic diagnoses, 48 tumors were differ-
entiated-type adenocarcinomas, and 68 tumors were undifferentiated-type adenocarcinomas.
Circulating tumor cells in patients with gastric cancer
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Fig 1. Circulating tumor cells (CTCs). CTCs were defined as captured cells that were CK+ or EpCAM+,
CD45-, and DAPI+ and had a diameter >8 μm.
https://doi.org/10.1371/journal.pone.0180251.g001
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Regarding T and N stages, 63, 13, 15 and 24 tumors were T1, T2, T3, and T4, respectively, and
69, 15, 15, and 17 tumors were N0, N1, N2, and N3, respectively. No patients had distant metas-
tases at the time of surgery. Lymphatic invasion, vascular invasion, and perineural invasion
were present in 44, 17, and 42 tumors, respectively. Regarding mucin phenotype, 60, 14, 24, and
18 tumors were gastric type, gastrointestinal type, intestinal type, and null type, respectively.
Thresholds for differentiating patients with gastric cancer from healthy
controls
Fig 2 shows a scatter plot of CTC values from healthy controls and patients with gastric cancer.
CTCs were identified in 3 of 31 healthy controls (CTC counts: 2.5, 5, and 5 per 7.5 mL of
Table 1. Baseline clinicopathologic characteristics of 116 patients with gastric cancer.
Median age, years (range) 60 (33–89)
Sex, n (%)
Male 74 (64)
Female 42 (36)
Location, n (%)
Upper third 21 (18)
Middle third 43 (37)
Lower third 52 (45)
Histologic type, n (%)
Differentiated type 48 (41)
Undifferentiated type 68 (59)
Median size, cm (range) 4 (2–13)
T stage, n (%)
T1 63 (54)
T2 13 (11)
T3 15 (13)
T4 25 (22)
N stage, n (%)
N0 69 (59)
N1 15 (13)
N2 15 (13)
N3 17 (15)
Lymphatic invasion, n (%)
Absent 72 (62)
Present 44 (38)
Vascular invasion, n (%)
Absent 99 (85)
Present 17 (15)
Perineural invasion, n (%)
Absent 74 (64)
Present 42 (36)
Mucin phenotype, n (%)
Gastric type 60 (52)
Intestinal type 14 (12)
Gastrointestinal type 24 (21)
Null type 18 (15)
https://doi.org/10.1371/journal.pone.0180251.t001
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blood). In contrast, CTCs were identified in 105 (91%) of 116 patients with gastric cancer. The
median CTC count among these patients was 19.5 (range, 0–835) per 7.5 mL of blood.
A ROC curve was created to identify the optimal CTC threshold value for differentiating
patients with gastric cancer from healthy controls (Fig 3). Sensitivity and specificity were opti-
mized using a threshold CTC count of 2 per 7.5 mL of blood. Of the 102 persons with a CTC
level2 per 7.5 mL of blood, 99 (97.1%) had gastric cancer. However, of the 45 persons with a
CTC level <2 per 7.5 mL of blood, 28 (62.2%) were healthy controls. Therefore, for differenti-
ating patients with gastric cancer from healthy controls, this model had a positive predictive
value of 97.1% and negative predictive value of 62.2%, resulting in a sensitivity of 85.3% and
specificity of 90.3% (Table 2).
Association between circulating tumor cells and clinicopathologic
findings in gastric cancer
Of the 116 patients with gastric cancer, 99 (85%) had2 CTCs per 7.5 mL of blood. CTCs
were not found to associate with histologic type or tumor size (P = 0.985 and P = 0.429, respec-
tively; Table 3). Although CTCs did not associate with T or N stage (P = 0.581 and P = 0.510,
respectively), CTCs were detected in >80% of patients with T1-stage and N0-stage disease.
CTCs were also not found to associate with lymphatic or vascular invasion (P = 0.713 and
P = 0.765, respectively).
Association between circulating tumor cells and mucin phenotypes in
gastric cancer
MUC2, MUC5AC, MUC6, and CD10 expression levels were increased in 32 (28%), 80 (69%),
28 (24%), and 12 tumors (10%), respectively. CTCs did not associate with mucin expression
(Table 4). CTCs were detected in 53 (88%) of 60 gastric type, 21 (87%) of 24 intestinal type, 11
(79%) of 14 gastrointestinal cancers, and 14 (78%) of 18 null type cancers. There were no dif-
ferences in CTCs according to mucin phenotype (P = 0.606).
Fig 2. Circulating tumor cells (CTCs) in healthy controls and patients with gastric cancer. CTCs were
identified in 3 of 31 healthy controls and 105 of 116 patients with gastric cancer.
https://doi.org/10.1371/journal.pone.0180251.g002
Circulating tumor cells in patients with gastric cancer
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Discussion
In the present study, CTCs were identified in 105 (91%) of 116 patients with gastric cancer,
and a threshold of2 CTCs per 7.5 mL of blood was useful for differentiating patients with
gastric cancer from healthy controls. However, no associations were observed between CTCs
and clinicopathologic features such as histologic type, T stage, N stage, and mucin phenotype.
To our knowledge, this is the first report to demonstrate FAST-based CTC detection as an
early diagnostic biomarker for gastric cancer.
Numerous reports have described the isolation and characterization of CTCs from
patients with gastric cancer [20]. Because CTCs have been observed at very low concentra-
tions (10−7–10−8) relative to normal peripheral blood cells in samples from patients with
cancer [21], CTC detection in blood requires highly sensitive, specific, and reproducible
Fig 3. Receiver operating characteristic (ROC) curve. The value of circulating tumor cells (CTCs) showed
an area under the ROC curve of 0.928 (95% confidence interval: 0.885–0.971, P < 0.001). To identify the
optimal CTC threshold value for differentiating patients with gastric cancer from healthy controls, the
sensitivity and specificity were optimized using a threshold count of 2 CTCs per 7.5 mL of blood.
https://doi.org/10.1371/journal.pone.0180251.g003
Table 2. Sensitivity, specificity, and positive and negative predictive values of circulating tumor cells for the differentiation of patients with gastric
cancer from healthy controls.
Sensitivity
(%, 95% CI)
Specificity
(%, 95% CI)
Positive predictive value
(%, 95% CI)
Negative predictive value
(%, 95% CI)
CTC2 per 7.5 mL of blood 85.3
(81.4–87.2)
90.3
(75.6–97.4)
97.1
(92.6–99.2)
62.2
(52.1–67.1)
CTC, circulating tumor cell; CI, confidence interval.
https://doi.org/10.1371/journal.pone.0180251.t002
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methods. Immunocytochemistry, RT-PCR procedures, flow cytometry, and CellSearch sys-
tem have all been used to detect these rare CTCs [20]. Of these, the CellSearch system is the
first and only FDA-approved test applicable for CTC detection in patients with metastatic
breast, prostate, or colorectal cancer. This system is based on the enumeration of epithelial
cells, which are separated from the blood using EpCAM antibody-coated magnetic beads
and identified with fluorescently labeled antibodies against cytokeratin and a fluorescent
nuclear stain. However, the CellSearch system has several shortcomings, including an inabil-
ity to capture and analyze cells lacking tumor marker expression, poorly differentiated cells,
or circulating tumor stem cells [22]. Therefore, other CTC acquisition methods have been
pursed, including isolation by size, in which tumor cells are isolated and individually filtered
Table 3. Clinicopathologic features of patients with gastric cancer according to the level of circulating tumor cells.
CTC <2
(n = 17)
CTC2
(n = 99)
P-value
Sex, n (%) 0.120
Men 8 (11) 66 (89)
Women 9 (21) 33 (79)
Age, n (%) 0.216
60 years 11 (19) 48 (81)
>60 years 6 (11) 51 (89)
Location, n (%) 0.008
Upper third 4 (19) 17 (81)
Middle third 1 (2) 42 (98)
Lower third 12 (23) 40 (77)
Histologic type, n (%) 0.985
Differentiated type 7 (15) 41 (85)
Undifferentiated type 10 (15) 58 (85)
Tumor size (cm, mean ± SD) 5.2 ± 3.2 4.6 ± 2.7 0.429
T stage, n (%) 0.581
T1 7 (11) 56 (89)
T2 2 (15) 11 (85)
T3 3 (20) 12 (80)
T4 5 (20) 20 (80)
N stage, n (%) 0.510
N0 8 (12) 61 (88)
N1 2 (13) 13 (87)
N2 3 (20) 12 (80)
N3 4 (24) 13 (76)
Lymphatic invasion, n (%) 0.713
Absent 14 (14) 85 (86)
Present 3 (18) 14 (82)
Vascular invasion, n (%) 0.765
Absent 10 (14) 62 (86)
Present 7 (16) 37 (84)
Perineural invasion, n (%) 0.314
Absent 9 (12) 65 (88)
Present 8 (19) 34 (81)
CTC, circulating tumor cell; SD, standard deviation.
https://doi.org/10.1371/journal.pone.0180251.t003
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from blood cells based on the differential size of epithelial cells, have been pursued [23].
Accordingly, many researchers have developed lithography-based microfilters with con-
trolled pore sizes and shapes to increase porosity and thus enhance isolation [24–26]. How-
ever, these methods require blood samples to be diluted and/or fixed to achieve higher
recovery and avoid frequent clogging. More importantly, these methods are not suitable for
mass production [27, 28]. Commercial size-based CTC isolation kits utilize less expensive
track-etched polycarbonate membranes instead of lithography-based microfilters. However,
the non-uniform and randomly distributed pores and low porosity of these membranes can
cause inconsistent and lower-than-desired recoveries and purity [28, 29]. Here, we used a
centrifugal microfluidic device operated in FAST mode to overcome the limitations of track-
etched based filtration using a hydrodynamic approach [10]. FAST provides uniform, clog-
free, and efficient filtration under a lower pressure drop when compared to conventional
separation, leading to highly sensitive (>95.9% recovery), selective (~2.5 log depletion of
white blood cells), rapid (>3 mL/min), and label-free isolation of CTCs from whole blood
without prior sample treatment [10, 11].
In the present study, CTCs were identified in 3 (9.6%) of 31 healthy controls, consistent
with the results of a previous study, in which CTCs were detected in 8 (5.5%) of 145 healthy
controls [30]. Of the 116 patients with gastric cancer, CTCs were identified in 105 (91%)
patients, higher than the positive rates (10.8–69%) reported previously by using the CellSearch
system [5, 6, 31]. We used a ROC curve to identify the optimal threshold level of CTCs for dif-
ferentiating patients with gastric cancer from healthy controls, and defined this threshold as
2 CTCs per 7.5 mL of blood, similar to previous reports [30, 31]. Using this threshold, 99
(85%) of 116 patients with gastric cancer were found to have2 CTCs per 7.5 mL of blood,
and this rate was similar irrespective of T stage and N stage. Overall, the sensitivity and speci-
ficity values for the threshold of 2 CTCs per 7.5 mL as a differentiator of patients with gastric
Table 4. Mucin expression in gastric cancer according to the level of circulating tumor cells.
CTC <2
(n = 17)
CTC 2
(n = 99)
P-value
MUC2 expression, n (%) 1.000
Negative 12 (14) 72 (86)
Positive 5 (16) 27 (84)
MUC5AC expression, n (%) 0.397
Negative 7 (19) 29 (81)
Positive 10 (12) 70 (88)
MUC6 expression, n (%) 1.000
Negative 13 (15) 75 (85)
Positive 4 (14) 24 (86)
CD10 expression, n (%) 1.000
Negative 16 (15) 88 (85)
Positive 1 (8) 11 (92)
Mucin phenotype, n (%) 0.606
Gastric type 7 (12) 53 (88)
Intestinal type 3 (13) 21 (87)
Gastrointestinal type 3 (21) 11 (79)
Null type 4 (22) 14 (78)
CTC, circulating tumor cell.
https://doi.org/10.1371/journal.pone.0180251.t004
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cancer from healthy controls were 85.3% and 90.3%, respectively. These results suggest the
potential use of CTCs as an early diagnostic biomarker of gastric cancer.
A recent meta-analysis of CTCs in patients with gastric cancer suggested correlations of
CTCs with tumor staging, histologic type, and lymphovascular invasion [20]. However, most
studies included in that meta-analysis detected CTCs using RT-PCR or immunohistochemis-
try; only 2 studies used the CellSearch system. In those latter studies, however, CTCs were
found to correlate with tumor staging and lymphovascular invasion [5, 31]. In contrast, the
present study found no associations of the CTC level with clinicopathologic features. The dif-
ference between our results and those of previous studies might be attributable to heterogene-
ity in the baseline clinicopathologic characteristics and the use of different CTC detection
methods.
As shown in this report, CTCs can be detected in cancer patients without clinically detect-
able metastasis [32]. However, not all CTCs have the potential to develop into metastases; only
a small subset with stem cell-like or epithelial-mesenchymal transition properties can survive
and migrate to distant sites to establish secondary tumors [33]. Therefore, the subclassification
of detected CTCs using stem cell or epithelial-mesenchymal transition markers would provide
more useful information for tumor stage evaluation and prediction of recurrence and metasta-
sis. Furthermore, CTC monitoring could be useful for predicting tumor progression, progno-
sis, and the effects of chemotherapy in patients with gastric cancer [5, 6]. Therefore, FAST-
based CTC measurement is advantageous because it can be performed easily and noninva-
sively at any time.
Nonetheless, this study has several limitations. First, because we focused on the presence of
CTCs at the time of surgery, we did not examine long-term follow-up results, such as recur-
rence and survival, based on the level of CTCs. Secondly, we attempted to associate CTCs with
clinicopathologic findings based on the final pathologic results and therefore did not include
patients with distant metastases. In the future, we plan to analyze the roles of CTCs in predict-
ing the long-term (at least 2 years) outcomes and responses to chemotherapy in patients with
distant metastases of gastric cancer. Thirdly, because a loss of epithelial markers can occur
during progression to malignancy [34], the use of an EpCAM antibody-based CTC detection
method creates a potential limitation to the sensitivity of the current generation of CTC detec-
tion platforms [35].
Conclusions
Although the clinical feasibility of CTC assessment for gastric cancer staging was not proven,
our study results suggest a potential role of FAST-based CTC detection as an early diagnostic
biomarker of gastric cancer. These results should be further supported by additional large,
prospective multi-center studies. In addition, the role of CTCs as a biomarker predictive of
patients’ prognoses and responses to chemotherapy should be investigated during a long-term
follow-up.
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